Table V.

Univariate and multivariate analyses of clinicopathological variables and the expression of CXCR1/2 with regard to TNM stage.

	Univariate analysis			Multivariate analysis
Variables	OR	95% CI	P-value	OR	95% CI	P-value
Gender (male vs. female)	0.754	0.246–2.312	0.062	0.610	0.074–5.053	0.646
Age (<60 vs. ≥60 years)	1.022	0.405–2.581	0.963	0.806	0.167–3.900	0.789
Differentiation (poor vs. moderate, good)	0.570	0.229–1.422	0.228	0.549	0.108–2.804	0.471
CXCR1/2 (negative, weak vs. strong)	39.291	9.061–169.864	<0.001	204.793	14.850–2827.081	<0.001
pAKT (negative, weak vs. strong)	1.193	0.412–3.463	0.744	5.435	0.775–38.081	0.089
pERK (negative, weak vs. strong)	5.186	1.786–15.059	0.002	2.049	0.336–12.516	0.437
Ki-67 (negative, weak vs. strong)	1.111	0.400–3.089	0.840	0.849	0.082–8.837	0.891
Cyclin D1 (negative, weak vs. strong)	1.506	0.474–4.783	0.488	1.563	0.166–14.688	0.697
EGFR (negative, weak vs. strong)	1.091	0.357–3.330	0.879	0.149	0.013–1.766	0.131
Bcl-2 (negative, weak vs. strong)	1.560	0.631–3.857	0.336	3.436	0.481–24.582	0.219
Bax (negative, weak vs. strong)	1.127	0.315–4.039	0.854	0.677	0.071–6.449	0.734
VEGF (negative, weak vs. strong)	0.604	0.242–1.507	0.280	0.499	0.072–3.483	0.483
MVD (<20 vs. ≥20)	13.383	4.280–41.846	<0.001	28.905	4.092–204.384	0.001
MMP-9 (negative, weak vs. strong)	0.988	0.290–3.367	0.985	0.288	0.020–4.166	0.361
MMP-2 (negative, weak vs. strong)	0.419	0.045–3.881	0.443	0.260	0.003–26.050	0.566
E-cadherin (negative, weak vs. strong)	0.245	0.052–1.121	0.075	0.067	0.003–1.697	0.101

Patients were divided into two groups of age assessed with 60 years as the cut-off value. CXCR1/2, C-X-C chemokine receptor types 1/2; OR, odds ratio; MVD, microvessel density; 95% CI, 95% confidence interval.